|ASMB -- USA Stock|| |
USD 41.82 0.71 1.67%
Mr. Anthony E. Altig is Independent Director of ASSEMBLY BIOSCIENCES, Inc., since January 2012. Since 2008, Mr. Altig was the Chief Financial Officer of Biotix Holdings, Inc., a company that manufactures microbiological consumables. From 2004 to 2007, Mr. Altig served as the Chief Financial Officer of Diversa Corporationrationration, a public company developing specialized industrial enzymes. Prior to joining Diversa, Mr. Altig served as the Chief Financial Officer of Maxim Pharmaceuticals, Inc., a public biopharmaceutical company. In addition, Mr. Altig serves as a director and chairman of the audit committee for TearLab Corporationrationration, a publicly traded eyecare technology company, and served as a director of Optimer Pharmaceuticals, Inc., a pharmaceutical company, which was a public company until its acquisition by Cubist Pharmaceuticals, Inc. in October 2013.
Age: 60 Director Since 2012
Anthony Altig Latest Insider Activity
The company has return on total asset (ROA)
of (24.41) %
which means that it has lost $24.41 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE)
of (44.36) %
meaning that it created substantial loss on money invested by shareholders.
Assembly Biosciences, Inc. operates as a clinical stage biotechnology company. Assembly Biosciences, Inc. was founded in 2005 and is headquartered in Carmel, Indiana. Assembly Biosciences operates under Biotechnology classification in USA and traded on Nasdaq Capital Markets. It employs 79 people.Assembly Biosciences (ASMB) is traded on Nasdaq Capital Markets in USA. It is located in NEW YORK, U.S.A and employs 79 people. Assembly Biosciences is listed under Pharmaceutical Products category by Fama And French industry classification.
Assembly Biosciences Leadership Team
|Uri Lopatin, President, Ph.D|
|Helen Kim, Director, MBA|
|Myron Holubiak, Director|
|Lee Arnold, Executive, Ph.D|
|Anthony Altig, Director|
|Richard Colonno, Executive|
|Graham Cooper, COO, MBA|
|William Ringo, Chairman, MBA|
|Susan Mahony, Director|
|Richard DiMarchi, Director, Ph.D|
|Miguel Barbosa, Executive, Ph.D|
|Thomas Rollins, Executive|
|Mark Auerbach, Director|
|Derek Small, CEO|
|Alan Lewis, Director, Ph.D|
|David Barrett, COO|
Stock Performance Indicators
Most of Macroaxis users are presently bullish on Assembly Biosciences. What is your sentiment towards investing in Assembly Biosciences? Are you bullish or bearish?
and pair trading evaluation for B of A and Citigroup
. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return
Check also Trending Equities
. Please also try Equity Analysis
module to research over 250,000 global equities including funds, stocks and etfs to find investment opportunities.